May 7, 2021
DANVILLE — The National Cancer Institute (NCI), part of the National Institutes of Health, has awarded a 5-year, $3.6 million contract to Geisinger to study the role of genetic variation in cancer.
Researchers from Geisinger and the NCI’s Division of Cancer Epidemiology and Genetics (DCEG) will analyze genetic data from Geisinger’s MyCode Community Health Initiative, a precision medicine project with more than 276,000 consented participants. The work will be led by David J. Carey, Ph.D., professor and chair of the Department of Molecular and Functional Genomics at Geisinger and a MyCode principal investigator, and Douglas Stewart, M.D., a senior investigator at DCEG.